Within the last decade newly developed asthma monoclonal antibody therapies targeting specific components of the Type‐2 inflammatory pathway have been brought to clinic for example, anti‐IL‐5 (Mepolizumab), anti‐IL‐4/13 (Dupilumab) demonstrating steroid sparing effects and efficacy in reducing exacerbations [10, 11, 12]. This evidence concerns the gene IL4 and asthma.